# SEINDA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/seinda

- Industry: Pharmaceuticals
- Headquarters: Guangzhou, China
- Website: www.seindabio.com
- Latest round: Series A (Jul 17, 2023)
- Investors on record: 1

## About

Established in 2015, and based in Guangzhou, China, Shengyuan Medicine doing business named SEINDA, is a pharmaceutical company that engaged in production, and sales of ophthalmic medical devices and new drugs. Its production bases in Guangzhou, which a clean production workshop, a microorganism test laboratory, physical and chemical inspection laboratory, and warehousing facilities. In July 2023, SEINDA raised series A+ funding from new investor Guangzhou Guoju Venture Capital.

Its products can be divided into ophthalmic point-of-care testing (POCT) product, Covid-19 antigen test product, new drugs for eyes diseases. The ophthalmic point-of-care testing (POCT) product include micro-capillary fluid collectors, fluid collectors POC test kits, and i-Immundx™ analyzer, which enable physicians to detect etiology of ocular disorders, and can quantitative measurements. New drugs pipelines include SY101 for myopia, SY201 for dry eye, and SY-301 for presbyopia. 

The company will use the series A+ funding for clinical development of the dry eye drug SY201, and commercial development of POCT products.

## Funding rounds

- Series A, Jul 17, 2023 — Guangzhou Guoju Venture Capital

## Investors

- Guangzhou Guoju Venture Capital (https://capitalatlas.ai/funds/guangzhou-guoju-venture-capital) — Series A